RPG Life Sciences is moving beyond individual acquisitions to assemble a larger active pharmaceutical ingredient (API) business, using recently acquired manufacturing capacity, product portfolios and regulatory approvals as the foundation for export-led growth. The company’s strategy illustrates how Indian drugmakers are attempting to capture more value in pharmaceutical supply chains while addressing the operational challenge of integrating underused assets.
The company has spent ₹215 crore on two API-related acquisitions in five weeks and has more than ₹500 crore available for additional opportunities, according to a Business Standard report based on an interview with Managing Director Ashok Nair. RPG Active Pharma (RPGAP), a wholly owned subsidiary, agreed last week to acquire the API and intermediates business of Raghava Life Sciences for up to ₹135 crore. That followed the ₹80-crore acquisition of Actis Generics on July 29.
The immediate change is one of scale. RPGAP’s manufacturing capacity has risen from 110 kilolitres to 505 kilolitres, while its product portfolio has expanded from 14 products to 45. Its customer base has grown from 123 to more than 250, and employee strength has increased from 217 to over 500. The company’s research and development pipeline has also expanded from 12 products to 28, Nair told the newspaper.
These figures indicate that RPG is not treating the transactions simply as capacity purchases. The acquisitions add manufacturing infrastructure, chemistry capabilities, customers, products and regulatory credentials at the same time. That combination is central to the company’s stated “buy-and-build” approach, in which an enlarged platform is expected to generate more value through integration and higher utilisation.
## From capacity addition to business integration
The Raghava transaction is particularly important because it brings an approximately 300-kilolitre facility near Hyderabad into RPGAP’s network. The plant has EU-GMP and WHO-GMP approvals, while the business holds regulatory credentials including a Certificate of Suitability to the European Pharmacopoeia, EU Written Confirmation and a Korea Drug Master File approval.
RPG’s emphasis on regulatory access reflects the way API manufacturing is connected to international market entry. Physical capacity alone does not guarantee export growth. Products must be supported by the relevant approvals, documentation, quality systems and customer relationships. By acquiring a business with regulatory credentials and an existing product base, RPG is seeking to reduce the time and resources required to build those capabilities from the ground up.
The company is also resisting a narrow interpretation of the US market. Nair said US Food and Drug Administration-approved manufacturing capability remains part of RPG’s longer-term strategy, but the company would not acquire a facility only because it had that approval. The chemistry, product basket, customers, utilisation potential and economics would all need to be compelling.
That position places strategic fit above acquisition count. RPG has not set a predetermined number of deals, with the timing of further transactions expected to depend on valuation, integration readiness, returns and the quality of the target business. The approach is significant because a rapidly assembled portfolio can create operational complexity if products, plants, regulatory systems and customers are not integrated effectively.
The available figures show both the opportunity and the gap that RPG must close. Actis and Raghava together generated about ₹70 crore in FY26 revenue. At the same time, RPG believes the Raghava facility alone could support approximately ₹200 crore in annual revenue at fuller utilisation without significant incremental capital expenditure. The difference between current revenue and potential revenue is therefore expected to be addressed primarily through customer additions, geographic expansion and integration with Actis and RPG’s existing API operations.
## The utilisation challenge
Underused manufacturing infrastructure is a recurring issue in asset-intensive businesses: installed capacity can exist without producing a proportionate level of revenue. In RPG’s case, the acquisition thesis depends on converting capacity into a broader product and customer platform. The company will need to match available production capability with demand, maintain regulatory compliance and develop a product mix that supports improved economics.
The reported expansion from 110 kilolitres to 505 kilolitres makes the utilisation question more important, not less. A larger capacity base can provide room for growth, but it also raises the importance of manufacturing efficiency, scheduling, quality control and commercial execution. The acquisition of Raghava gives RPG access to infrastructure that can support higher revenue, but the reported potential is not the same as realised performance.
RPGAP is being developed primarily as an independent merchant API and advanced-intermediates business rather than as a captive supplier to RPG Life Sciences’ formulations business. Third-party customers, exports and selected contract development and manufacturing organisation opportunities are expected to constitute the larger growth opportunity, according to Nair.
That structure broadens the addressable customer base. A captive model could provide internal demand, but an independent merchant business requires RPGAP to compete for external orders and build relationships across markets. It also means that the company’s manufacturing assets must serve a commercially diverse portfolio rather than being aligned only to the requirements of its parent company’s formulations operations.
## Supply-chain diversification and export ambition
The company’s strategy comes as global drugmakers seek to diversify pharmaceutical supply chains and reduce excessive dependence on China, the report said. RPG’s response is not limited to adding production volume. It is attempting to combine capacity with differentiated chemistry, regulatory access, export capability and a wider customer base.
The source material does not establish the scale of any broader market shift or quantify how much business could move to India. It does, however, show how one Indian drugmaker is positioning its API platform around the requirements of international customers. Regulatory approvals and export credentials are being treated as strategic assets alongside plants and equipment.
This is also why the Hyderabad facility’s existing infrastructure matters. If the facility can support higher revenue without significant incremental capital expenditure, the company may be able to expand the business through commercial and operational measures before committing heavily to new construction. That does not eliminate the need for investment: RPG has said it plans to deploy capital towards further acquisitions, manufacturing expansion, product development and regulatory access. It does indicate that the first phase of growth is expected to come from better use of assets already acquired.
RPG’s debt-free position gives it another source of flexibility. More than ₹500 crore is available for potential opportunities, but the company’s own criteria suggest that capital will not automatically translate into more deals. Strategic fit, valuation, integration readiness and returns will determine whether additional acquisitions proceed.
## What the evidence confirms
The reported numbers confirm a rapid increase in RPGAP’s operating footprint. Capacity has increased nearly fivefold from 110 kilolitres to 505 kilolitres; the product portfolio has more than tripled from 14 to 45; and the customer base has grown from 123 to more than 250. Employee strength and the research pipeline have also expanded substantially.
The evidence also confirms that RPG’s strategy is designed around a combination of assets rather than a single facility. Actis contributes to the enlarged platform, while Raghava adds installed capacity, products, customers and regulatory approvals. The company expects integration to create a larger merchant API and advanced-intermediates business with export and selected CDMO opportunities.
What remains unestablished is whether the acquired businesses will reach the revenue potential described by management, how quickly capacity utilisation will rise and whether further acquisitions will be completed. The report provides management’s assessment of the opportunity, but not an independent performance review of the acquired assets or a detailed integration timetable.
The next phase will therefore be measured less by the number of acquisitions than by the conversion of acquired capability into recurring revenue. RPG’s buy-and-build model has created a substantially larger platform in a short period. Its performance will depend on whether the company can integrate that platform, fill underused capacity, expand its external customer base and secure regulatory access without weakening the economics that justified the acquisitions in the first place.
